Potsdam

• Lp(a) lowering study of pelacarsen (TQJ230) with background inclisiran in participants with elevated Lp(a) and established ASCVD Recruiting
  2024-516356-18-00 5 2026-02-17 Atherosclerotic cardiovascular disease (ASCVD)
• Efficacy of top-down therapy with mirikizumab versus standard of care with azathioprine in patients with newly diagnosed moderate-to-severe … Recruiting
  2025-522585-72-00 6 2025-12-05 ulcerative colitis
• TYPER Recruiting
  2024-520290-12-00 6 2025-11-04 Hormone receptor–positive (HRpos)/human epidermal growth factor recept
• A study to investigate the efficacy and safety of SAR444336 in adults with microscopic colitis in clinical remission. Recruiting
  2024-519495-83-00 4 2025-10-28 Digestive system diseases
• EASi-PROTKT™ - A study to test vicadrostat (BI 690517) taken together with empagliflozin in people with type 2 diabetes, high blood pressure … Recruiting
  2025-521188-11-00 5 2025-10-15 Type 2 diabetes
• A Phase 3, randomized, parallel-group, double-blind, multicenter study investigating the safety and efficacy of NT 201 compared with placebo … Recruiting
  2025-520499-24-00 5 2025-10-01 Moderate to Severe Platysma Prominence
• Mirikizumab and Tirzepatide Administered in Adult Participants With Moderately to Severely Active Crohn’s Disease and Obesity or Overweight: … Recruiting
  2024-520210-21-00 5 2025-09-19 Crohn’s Disease
• A study to investigate the efficacy and safety of brivekimig in adult participants with ulcerative colitis. Recruiting
  2024-515241-41-00 4 2025-09-10 Ulcerative Colitis
• A Trial to Test How AZD0780 Affects Serious Heart, Stroke, or Vascular Problems in Patients with Heart, Stroke or Vascular Disease or at Hig … Recruiting
  2025-520519-14-00 5 2025-09-03 Atherosclerotic Cardiovascular Disease
• ABCSG 63 / ERIKA: Elacestrant and RIbociclib in Ki67-tested endocrine responsive breAst cancer: An open-label, two-arm, randomized, phase I … Recruiting
  2023-505758-17-00 4 2025-08-21 endocrine-responsive HER2-negative early breast cancer
• A Study to Assess safety and Effectiveness of the Inavolisib Plus a CDK4/6 Inhibitor and Letrozole Versus Placebo Plus a CDK4/6 Inhibitor an … Recruiting
  2024-516162-11-00 5 2025-07-14 Endocrine-Sensitive phosphatidylinositol 3-kinase (PIK3CA)-Mutated, Ho
• A study to investigate efficacy and safety of SAR441566 in patients with ulcerative colitis Recruiting
  2025-520705-12-00 4 2025-06-24 Colitis Ulcerative
• A trial to learn how well baxdrostat with dapagliflozin works compared to dapagliflozin on clinical outcomes alone and how safe it is in adu … Recruiting
  2023-506460-14-00 5 2025-05-07 Chronic kidney disease (CKD) and hypertension.
• SURVIVE HERoes – A randomized Secondary Adjuvant Treatment Intervention study comparing Trastuzumab-Deruxtecan to SOC therapy in eBC Patient … Recruiting
  2024-516173-76-01 5 2025-04-22 HER2-positive or HER2-low (incl. ultra-low) early breast cancer
• 5% KOH solution vs placebo treatment of actinic keratosis with different treatment duration Recruiting
  2024-514277-21-00 5 2025-03-19 Actinic keratosis
• A trial to learn if Dato-DXd with rilvegostomig, or rilvegostomig alone, is safe and works compared with pembrolizumab in people who have ad … Recruiting
  2023-505077-32-00 5 2025-01-28 Locally-advanced or metastatic non-squamous non-small cell lung cancer
• A clinical study comparing the efficacy and safety of a new cream containing ivermectin with the efficacy and safety of the originator produ … Recruiting
  2023-505897-13-00 5 2024-12-02 Papulopustular Rosacea
• Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician’s Choice in Patients With Triple Negative Breast Cancer … Recruiting
  2024-512279-10-00 5 2024-11-25 Triple Negative Breast Cancer
• NeoAdjuvant study comparing sacituzumab govitecan versus sacituzumab govitecan+pembrolizumab treatment in low-risk, triple-negative early br … Recruiting
  2023-508787-29-00 4 2024-10-10 Triple-negative early breast cancer with low risk for recurrence
• Clinical study on the treatment of scabies disease Recruiting
  2024-513288-14-00 5 2024-10-01 Scabies
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Adaptive Phase 3 Study to Evaluate the Efficacy and Safety of Sinecatechins (De … Recruiting
  2022-502811-12-00 5 2024-09-04 Actinic Keratosis (AK) of the Scalp and/or the Face.
• Clinical trial of MK-2870 in combination with pembrolizumab in people who have had surgery to treat triple negative breast cancer Recruiting
  2023-504962-52-00 5 2024-07-10 Triple negative breast cancer.
• Evaluation of the efficacy and safety of a new gel containing 10 mg/g Clindamycin and 0.25 mg/g Tretinoin vs. the originator Acnatac(R) 10 m … Recruiting
  2023-504552-10-01 5 2024-05-14 Papulopustular acne
• European Larynx Organ Preservation Study (ELOS) Recruiting
  2022-502751-61-00 4 2024-04-10 Advanced stage III, IVA, IVB laryngeal or II, III, IVA, IVB hypopharyn

Showing 25–48 of 95 trials